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Abstract: Bacterial biofilms are multicellular aggregates in which cells are embedded in an extracellular
matrix of self-produced biopolymers. Being refractory to antibiotic treatment and host immune
systems, biofilms are involved in most chronic infections, and anti-biofilm agents are being searched
for urgently. Epigallocatechin-3-gallate (EGCG) was recently shown to act against biofilms by strongly
interfering with the assembly of amyloid fibres and the production of phosphoethanolamin-modified
cellulose fibrils. Mechanistically, this includes a direct inhibition of the fibre assembly, but also triggers
a cell envelope stress response that down-regulates the synthesis of these widely occurring biofilm
matrix polymers. Based on its anti-amyloidogenic properties, EGCG seems useful against biofilms
involved in cariogenesis or chronic wound infection. However, EGCG seems inefficient against or
may even sometimes promote biofilms which rely on other types of matrix polymers, suggesting
that searching for ‘magic bullet’ anti-biofilm agents is an unrealistic goal. Combining molecular and
ecophysiological aspects in this review also illustrates why plants control the formation of biofilms
on their surfaces by producing anti-amyloidogenic compounds such as EGCG. These agents are not
only helpful in combating certain biofilms in chronic infections but even seem effective against the
toxic amyloids associated with neuropathological diseases.
Keywords: bacterial biofilm; functional amyloid; curli fibre; bacterial exopolysaccharides; bacterial
cellulose; chronic infection; antimicrobial
1. Introduction
Bacterial biofilms are ubiquitous multicellular aggregates which are usually attached to biotic
or abiotic surfaces in which bacteria are embedded in an extracellular matrix of self-produced
polymers [1–4]. Bacteria in biofilms are refractory to antibiotic treatment and host immune systems [5,6].
As a consequence, biofilms of pathogenic bacteria play crucial roles in chronic infections (e.g., of wounds,
soft tissue and the urinary tract or in cystic fibrosis (CF), laryngitis, otitis media, dental plaque, caries
and periodontosis) as well as in the colonization of catheters, artificial heart valves, orthopedic implants
and other intracorporal medical devices [7,8]. Notably, this biofilm-associated antibiotic tolerance is not
acquired by horizontal gene transfer or specific mutations in antibiotic targets as in classical antibiotic
resistance, but it is part of the normal bacterial physiological and regulatory repertoire.
With biofilms being key to chronic infections, the need for anti-biofilm compounds has become
apparent [8–11]. Unlike classical antibiotics, these are active at concentrations that do not interfere with
bacterial growth or survival but inhibit the formation of bacterial biofilms or disrupt already existing
biofilms by targeting biofilm-related structures or regulation. Thereby, they can act synergistically
with antibiotics and/or allow the immune system to attack bacteria that would otherwise be hidden
away in biofilms [9–13]. Screening large chemical libraries using high-throughput approaches has
been used to identify anti-biofilm compounds [14]. Alternatively, natural products originating from
plants, marine sponges or other biological sources have been tested [9,15–17]. The latter approach has
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revealed that numerous compounds, which naturally occur in plants, as well as complex plant extracts
indeed exhibit anti-biofilm activity [18].
Epigallocatechin-3-gallate (EGCG) and related catechins, which are not only the major polyphenols
in green tea (Camellia sinensis) but are also present in many other plants, have long been known to have
numerous benefits for human health (see other articles in this compendium; for a review, see [19]). This
also led to the first studies of EGCG’s effects on bacteria almost 20 years ago. After a short introduction
to biofims, this review will summarize reports on antimicrobial and above all anti-biofilm activities
of EGCG with a focus on the more recent studies that have addressed the molecular mechanisms of
action of EGCG. In addition, some bacterio-ecophysiological considerations will suggest that plants
may be a highly valuable source of many more anti-biofilm agents for which EGCG may serve as a
paradigm for the identification and analyses of mechanisms of action.
2. Bacterial Biofilms
The hallmark of bacterial biofilms is the presence of an extracellular polymeric matrix of complex
and variable composition [20,21]. This matrix often literally encases the bacterial cells and confers
structural stability, cohesion and elasticity to the biofilm, i.e., tissue-like properties, as most evident
from the buckling, folding and wrinkling of colony biofilms that form large-scale three-dimensional
morphological patterns [22–25]. Importantly, the matrix confers protection—for example, by trapping
phages or antimicrobial compounds and preventing access of predators—and by binding water, it
contributes to homeostatic conditions within the biofilm [3,6,21,26].
Biofilm matrices contain secreted proteins, some of which can form amyloid fibres,
exopolysaccharides and extracellular DNA, collectively termed extracellular polymeric substances
(EPS) [21]. Exopolysaccharides, which differ in their monosaccharide constituents, chemical
modifications, composition and types of glycosidic linkage, can be divided into two functional
classes with either aggregative or water-binding mucoid properties. A widely occurring example of
aggregative exopolysaccharides, which in general confer cohesion and structural stability to biofilms, is
cellulose [27–29]. In biofilm matrices of Escherichia coli and many other bacteria, cellulose is present as a
phosphoethanolamin-modified derivative (pEtN-cellulose) [30]. Other aggregative exopolysaccharides
are Psl and Pel of Pseudomonas [31], VPS of Vibrio cholerae [32] or the exopolysaccharide of Bacillus
subtilis [20]. Water-binding mucoid exopolysaccharides include colanic acid in enteric bacteria [33],
alginate in Pseudomonas aeruginosa [34] or other capsule polysaccharides. Exopolysaccharides are
synthesized by inner membrane-associated glycosyltransferases, which form the core of larger synthesis
and secretion complexes that include additional chaperone and pore components in the cell envelope
that guide the nascent polysaccharides to the cell surface [35]. Also, the pEtN group is transferred to
cellulose during its transit through the periplasm of E. coli and other Gram-negative bacteria [30].
Amyloid fibres are found in most natural biofilms [36–39]. Although differing in the sequences of
their protein subunits, amyloid fibres exhibit similar molecular superstructures classically consisting of
cross-beta sheets that further assemble into fibrils and finally fibres [39]. These are insoluble in sodium
dodecyl sulfate (SDS), proteinase K resistant and typically stain with Congo red (CR) and thioflavin
T/S. Recent data indicate a certain structural variability that also includes cross-beta helical structures
in some of these fibres, with cross-beta sheet conformations being promoted by low pH. Seeds of
these structures are able to template additional subunits into amyloid fibres (recently summarized
in [39]). From the perspective of bacteria, these fibres are ‘functional’ amyloids as they contribute
to aggregation and protective properties of biofilms [39] and can also serve the bacteria as virulence
factors in a host environment [40]. This is in contrast to the toxic amyloid fibres and plaques associated
with neurodegenerative disorders such as Alzheimer’s disease [41,42].
The best-studied biofilm-associated amyloids are curli fibres in E. coli and Salmonella enterica, which
also occur in other enterics [41,43,44]. In E. coli, curli fibres are co-regulated with pEtN-cellulose [45,46],
with the two fibres tightly associating into a composite material and forming a large-scale matrix
architecture within biofilms [24,29]. In many E. coli strains, curli fibres and cellulose are produced
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below 30 ◦C only, suggesting a major role in environmental biofilms. However, curli fibres and/or
pEtN-cellulose can also be produced at 37 ◦C by certain commensal or pathogenic E. coli [47,48]. In the
human intestine, curli fibres promote inflammation and can even trigger autoimmunity; i.e., also acting
as a virulence factor [40,49–51]. VariousPseudomonas species produce Fap fibres (for functional amyloids
in Pseudomonas) that have properties similar to curli fibres in enteric bacteria and that contribute to
cellular aggregation in biofilms as well as to the virulence of pathogenic pseudomonads [52]. Also,
Gram-positive bacteria use functional amyloids or amyloid-like fibres as biofilm matrix components.
These include TasA fibres made by Bacillus subtilis which feature both alpha-helical and cross-beta sheet
regions, with the fraction of the latter increasing at acidic pH [53,54]. Staphylococci generate various
extracellular matrix-localized fibres from phenol-soluble modulins and other proteins, although these
fibres do not seem to have all the properties of classical amyloids [39,40]. Finally, Streptococcus mutans,
which plays an important role in the formation of dental plaque and the oral dysbiosis leading to
caries [55], does not only produce exopolysaccharides it its biofilms, but also several exoproteins that
can form amyloid fibres (summarized in [39]).
As bacterial biofilms are highly diverse in their structure and matrix composition, several
model systems are currently used in research addressing both the formation and the inhibition of
biofilms [29,56]: (i) submerged biofilms that form on the walls of microtiter dishes in which the biofilms’
overall mass can be easily quantified by staining with crystal violet or other dyes, (ii) macrocolonies
growing for extended times at a semi-solid surface (agar)/air interface that are highly amenable to
genetic approaches, and (iii) pellicles forming at static fluid/air interfaces [56]. In searching for and
characterizing anti-biofilm agents, submerged biofilm models have been widely used, which due
to the low cost and simplicity of the procedure can also be adapted to high-throughput screening.
The more structured, CR-stainable and genetically analyzable macrocolonies as well as pellicles have
become important more recently, especially in attempts to clarify the molecular mechanisms of actions
of anti-biofilm agents.
3. EGCG Can Interfere with Bacterial Biofilm Formation
Green tea and its major constituent polyphenol EGCG, as well as many other plant-produced
polyphenols, have long been discussed as being beneficial for human health. which is usually attributed
to their general anti-oxidant and anti-inflammatory properties [19,57]. EGCG was also among one
of the first polyphenols to have its effects tested on bacteria. While relatively high concentrations of
EGCG were found to be toxic for various bacterial species (summarized by [58,59]), sub-inhibitory
concentrations indeed often show anti-biofilm activity. Thus, a mixture of green tea catechins, most
notably EGCG, was observed to reduce the adherence of S. mutans to surfaces, to somehow interfere
with bacterial glucosyltransferases involved in biofilm formation and to be anti-cariogenic in animals
and humans (summarized by [60,61]). EGCG was found to reduce submerged biofilm formation in
microtiter dishes as well as swarming of Burkholderia cepacia [62]. Similar results for submerged biofilm
formation were also obtained with Staphylococci [63], in particular with a series of ocular isolates of S.
aureus and S. epidermidis. Here, EGCG also reduced CR staining of colonies, and scanning electron
microscopy revealed strongly reduced matrix (‘slime’) production when Staphylococci were grown
on corneal epithelial cells in vitro [64]. Since then, submerged biofilm formation under laboratory
conditions was demonstrated to be impaired by EGCG for many more bacteria and in particular
pathogenic species, including enterohemorrhagic E. coli (EHEC) [65]; P. aeruginosa [66]; Porphyromonas
gingivalis (a member of the oral microbiota) [67,68]; Stenotrophomonas maltophilia isolated from the
lung of a CF patient (here, biofilm formation was also reduced by EGCG in a mouse model) [69];
Enterococcus faecalis [70]; Campylobacter jejuni [71]; Shewanella baltica [72]; Streptococcus pneumoniae [73];
again, S. mutans (where EGCG effects on dental biofilms were also tested in vivo; i.e., in dogs); [74] and
Fusobacterium nucleatum, another oral bacterium associated with periodontitis [75].
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4. Mechanisms of Action of EGCG on Bacterial Biofilms
In general, the early reports on EGCG’s effects were based on simply comparing the mass of bacteria
adhered to microtiter dishes in the presence and absence of EGCG and remained mostly descriptive
with respect to how the compound affected these biofilms. However, a few of the early as well as the
more recent studies have begun to address the question of the potential mechanisms of action of EGCG.
In some bacteria, such as P. aeruginosa, where biofilm formation involves intercellular communication
by quorum sensing, EGCG can somehow disturb signaling via autoinducer-1/LuxR-dependent or
autoinducer-2-dependent quorum sensing systems [62,66,72]. In several bacterial species, EGCG
can also attenuate the expression or activity of specific virulence factors, as observed for instance
for Shiga toxin in enterohemorrhagic E. coli (EHEC) [65,76] or staphylococcal enterotoxin B [77]. In
P. gingivalis, EGCG down-regulates flagella as well as factors involved in tissue destruction and
heme acquisition [68]. In E. faecalis, the EGCG-mediated down-regulation of certain virulence genes
was shown to involve the formation of hydroxyl radicals [70]. In S. pneumoniae, EGCG seems to
target specifically the virulence factors pneumolysin and sortase A [73]. Evidence of EGCG-mediated
membrane damage, iron chelation and reduced synthesis of hemolysin and hydrogensulfide was
reported for F. nucleatum [75]. Not all of these activities are necessarily direct, although the diversity of
effects suggests that EGCG may target a variety of cellular factors. It is also not clear which of these
effects are related to the anti-biofilm action of EGCG, although virulence and biofilm genes are often
co-regulated in complex manners. An exception is S. mutans, where the anti-biofilm effect of EGCG
seems related to its ability to reduce the expression of the three genes (gtfB, gtfC, gtfD) that encode
the glycosyltransferases that synthesize the biofilm-associated exopolysaccharides [78,79]. Although
a number of target processes have thus been identified, the molecular mechanisms by which EGCG
directly interferes with these remained mostly elusive in these studies.
In recent searches for molecular mechanisms targeted by EGCG, which are specifically related
to biofilms, several strategies have been followed and combined: (i) theoretical considerations based
on known molecular mechanisms of biofilm formation and control [12,80] to pinpoint appropriate
targets for inhibition; (ii) the use of plate-grown macrocolony biofilms as an experimental biofilm
system that—in contrast to microtiter dish-grown biofilms—allows to genetically characterize targets
and mechanisms of action [23,24,81]; and (iii) taking into account reports on how EGCG acts in other
systems, in particular in human biochemistry and physiology (see below), to get hints on direct
molecular mechanisms of action that may also occur in bacteria.
Appropriate targets for the inhibition of biofilm formation should be components or processes
that are crucial for the essential properties of most bacterial biofilms. While quorum sensing (QS)
is not as generally involved in biofilm control as initially assumed, and the biochemical nature
of QS signaling molecules is diverse, two other biochemical processes are widely conserved in
biofilms: the formation of amyloid fibres in many biofilm matrices [36] and the regulation by the
second messenger bis-(3′,5′)-cyclic diguanosine monophosphate (c-di-GMP), which rather ubiquitously
activates exopolysaccharide synthases and/or the expression of numerous genes involved in bacterial
biofilm formation [35,82–85]. Targeting a matrix component or process such as amyloidogenesis would
have the additional advantage that an inhibitory molecule could act from outside; i.e., it would not
have to traverse the entire cell envelope. This would be necessary to target for instance the cytoplasmic
c-di-GMP-synthesizing diguanylate cyclases, which all share the same catalytic mechanism in their
GGDEF domains (with this name standing for the highly conserved amino acids that define the active
centre) [86]. With respect to activities in a human biochemical context, EGCG was shown to prevent
amyloid formation in vitro by the A-beta and alpha-synuclein peptides, which are associated with
Alzheimer’s and Parkinson’s diseases, respectively, by inducing the formation of non-toxic off-pathway
oligomers [87–89]. Furthermore, EGCG inhibits amyloid fibre formation and even disrupts preformed
fibres of a mutant version of transthyretin which is associated with familial amyloidotic polyneuropathy,
where these extracellular fibres accumulate in connective tissue [90].
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Since these considerations suggested biofilm amyloid formation as a prime candidate for being
targeted by EGCG, the action of the compound was tested with macrocolony biofilms of commensal
and pathogenic E. coli strains [80], where the wrinkled morphotype depends on the high production
of amyloid curli fibres and pEtN-cellulose [24,29]. EGCG was indeed found to essentially eliminate
the entire CR-stainable extracellular matrix; i.e., curli fibres as well as pEtN-cellulose (Figure 1). This
drastic EGCG effect is due to a combination of (i) an anti-amyloidogenic activity, which results in
curli subunits (or oligomers) remaining soluble in sodium dodecyl sulfate (SDS) and diffusing into the
agar-containing medium below the biofilm, and (ii) triggering the cell surface stress response pathway
governed by the alternative sigma factor RpoE (σE; summarized in Figure 2). RpoE induces the small
regulatory RNA RybB, which directly binds to and interferes with the translation of the mRNA for the
biofilm regulator CsgD, which in turn is required to transcribe the curli genes as well as the gene for a
diguanylate cyclase that is essential to specifically activate cellulose synthase [80]. How exactly EGCG
triggers the RpoE-mediated cell envelope stress response is not yet clear; in part, because the signal
input generally is the least understood part of this stress response. However, EGCG was observed to
interact with lipid bilayers in cell membranes [91,92] and to induce small perforations and grooves in
the cell surface of EHEC; i.e., to clearly induce cell envelope damage [93].
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Figure 1. Epigallocatechin-3-gallate (EGCG) prevents the formation of amyloid curli fibres and
pEtN-cellulose; i.e., the two major components of the extracellular matrix of macrocolony biofilms
of E. coli. (A) Macrocolony biofilms of the standard E. coli K-12 strain W3110 (which produces only
curli fibres), its derivative strain AR3110 (which produces curli fibres and pEtN-cellulose) and the csgB
mutant derivative of strain R3110 (which produces only pEtN-cellulose) were grown on salt-free
complex medium agar l r five days at 28 ◦C. Plates were supplemented with Congo red (which
binds to and stains curli fibres as well tN-cellulose fibrils) and the indi ated concentrations of
EGCG, which results in a white colour indicating an absence of the polymeric matrix components. Note
that colony wrinkling patterns show characteristic differences depending on whether the matrix consists
of the curli/pEtN-cellulose composite or of either component alone. (B) High-resolution scanning
electron micrographs show tight surrounding of E. coli cells by the composite curli/pEtN–cellulose
matrix inside a macrocolony biofilm of strain AR3100 (left panel), whereas no matrix is present with
EGCG during growth (right panel). The few filamentous structures visible in the right panel are flagella,
which are unaffected by EGCG. The photographs shown here were previously publish d [80] under the
Creative Commons Attribution- NonCommercial-NoDerivatives license (CC-NC-ND); © the author.
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Besides showing anti-amyloidogenic activity of EGCG in a bacterial biofilm model, this study [80]
thus also revealed a novel target for biofilm interference–cell envelope stress responses, which in
multiple and complex manners respond to protein folding and assembly stress at the bacterial surface
and/or cell envelope. Under such stress conditions, these responses generally tune down the additional
synthesis of proteins destined for the cell envelope [94–97]. This includes proteins involved in large
molecular ‘construction sites’ such as the trans-cell envelope machineries for the controlled synthesis
of amyloid fibres and exopolysaccharides [80]. If this applies also to the subunits of conjugative pili, it
may explain the observation that EGCG can reduce conjugative R plasmid transfer [98]. Without even
having to enter bacterial cells, EGCG thus highly efficiently interferes with the macrocolony biofilm
formation of E. coli by synergistically targeting two crucial processes.
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interferes with the production of both amyloid curli fibres and pEtN-cellulose fibril—which together
form the fibrous matrix material visi le in the scanning electro micrograph f the surface of an E.
coli macrocolony biofilm shown in the upper rig t corner—by two separate but synergistically acting
processes: (i) EGCG directly interferes with th formati n of am loid fibres from curli subunits; and
(ii) EGCG induces the σE (RpoE)-mediated cell envelope stress response, which drives increased
synthesis of the small regulatory RNA RybB, whi h in turn reduces the x ression of CsgD as well as
of many outer membrane proteins (OMPs). The biofilm reg lator CsgD is requi d f r the expres ion
of the curli subunits as well as of DgcC, the diguanylate cyclase that produces the second m sseng r
c-di-GMP required to activate cellulose synthase as well as the associate phosphoethanolamin
(pEtN) modification system. The figure was previously published [80] under th CC-NC-ND license;
© the author.
In parallel, two studies with other bacterial amyloids also found these to be directly targeted by
EGCG. This applies to Fap fibres in certain types of P. aeruginosa biofilms, where the major subunit
FapC is remodeled into oligomers by EGCG, resulting in less stiff biofilms [99]. Since Fap fibres play
an important role in P. aeruginosa biofilms in the infected CF lung, a nebulized administration of EGCG
to CF patients was proposed as a potential treatment option which is worth further study [99]. The
fap genes occur in various branches of proteobacteria, including a number of pathogens, and besides
rendering biofilms highly aggregative and adherent, Fap fibres also seem to act as virulence factors [40].
Accordingly, the fap operon was highly activated in acute burn and chronical surgical wound infections
of P. aeruginosa in a mouse model [100]. Another line of evidence shows that EGCG prevents fibril
formation from the phenol-soluble modulins (PSM) of Staphylococcus species and can even disaggregate
preformed fibrils [101]. PSMs have been shown to contribute to virulence in various ways, although it
is still under debate whether these toxic activities require the fibrous forms of PSMs [40]. Given that
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P. aeruginosa and S. aureus are major biofilm-forming pathogens in chronic wound infection [102–104],
the interference of EGCG with the biofilm-associated amyloid or amyloid-like fibres of these two
pathogens and a putative therapeutic use of EGCG in this context certainly deserve further study.
5. Can EGCG Act Synergistically with Antibiotics on Bacterial Biofilms?
The high antibiotic tolerance of bacteria residing in biofilms severely impedes the antibiotic
treatment of many chronic infections [5,6,8,105,106]. Therefore, drugs that can prevent biofilm formation
are believed to also reduce biofilm-associated antibiotic tolerance, thereby allowing antibiotics to
act more efficiently on biofilm-associated infections [11,12,17]. However, biofilm-related antibiotic
tolerance is multifactorial, just as biofilm formation as a whole, is complex and involves many different
molecular processes [107]. Certain extracellular matrix components can restrict diffusion and trap
distinct antibiotics; i.e., the matrix can act as an effective filter that protects bacterial cells inside a biofilm
against antibiotic exposure [108–110]. The viscoelastic behavior of submerged biofilms also affects
water channels and thereby can influence rates of antibiotic penetration [111]. Moreover, most cells in a
densely populated biofilm are in a physiological state of stationary phase, which renders cells not only
tolerant against antibiotics that target the growing cell wall, but also induces pronounced multiple stress
resistance which may involve changes in certain antibiotic target structures and processes [56,112–114].
Furthermore, distinct antibiotic efflux pumps were found to be specifically induced in biofilm-dwelling
bacteria [115,116]. Finally, the formation of persister cells, which are in a non-growing and/or dormant
state, contribute to antibiotic tolerance in biofilms [117].
Because of this complexity, a given anti-biofilm agent is unlikely to counteract antibiotic tolerance
in general, just as it is unlikely to target all processes involved in biofilm formation; after all, it
is now clear that biofilm formation is not a process governed by a single hierarchically organized
developmental pathway [56,118–120]. As a consequence, a specific anti-biofilm agent such as EGCG
may contribute to suppress tolerance against a specific antibiotic in biofilms of a specific bacterial
species, but ‘magic bullet’ synergistic activities with various antibiotics against biofilms in general are
not to be expected. On the other hand, distinct activities of EGCG, which affect different molecular
targets in bacterial cells, may combine to counteract both the more classical antibiotic resistance as well
as biofilm-associated antibiotic tolerance. Notably, the underlying molecular mechanisms (e.g., efflux
pumps) are often principally similar, no matter whether these are acquired via mobile genetic elements
or are part of the ‘normal’ physiological repertoire activated in biofilms as described above.
Nevertheless, synergy between EGCG and certain antibiotics has been found in a series of studies,
although earlier studies in particular did not focus on counteracting biofilm-associated antibiotic
tolerance specifically. Thus, synergy of EGCG with β-lactams was found with methicillin-resistant
S. aureus (MRSA) [121–123]. By binding to peptidoglycan, EGCG restored antimicrobial activity of
penicillin against a penicillinase-producing S. aureus [124]. Besides reducing biofilm formation by
P. gingivalis, EGCG affected the growth of this oral bacterium synergistically with metronidazole [68].
EGCG also seems to interfere with the activities of certain antibiotic efflux pumps, as was shown for
tetracycline efflux in Staphylococci [63] and ciprofloxacin efflux in β-lactamase-producing Klebsiella
pneumoniae [125]. A biofilm-specific synergy was reported for P. aeruginosa, where EGCG remodels not
only Fap fibres in the biofilm matrix as described above, but also increases the susceptibility of the
biofilm to tobramycin [99].
On the other hand, specific anti-biofilm activity of EGCG and a reduction in biofilm-associated
antibiotic tolerance are not necessarily coupled. Under certain conditions, EGCG was found to even
promote biofilm formation and to increase tobramycin resistance of P. aeruginosa [126]. The underlying
molecular mechanisms have not been clarified but it is conceivable that by reducing amyloid fibre
formation, EGCG may lead to better exposure of some biofilm-promoting adhesin(s) on the bacterial
surface. Similarly, exposure to EGCG reduced susceptibility to several antibiotics in S. aureus [127].
Overall, more studies of potential synergies between EGCG and distinct antibiotics specifically
in biofilms of relevant pathogenic bacterial species are required while keeping in mind that even
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opposite and thus counterproductive effects can occur. Studies of synergies could be guided by the
increasing knowledge about the direct molecular targets of EGCG. For instance, the finding that
EGCG strongly reduces the formation of amyloid fibres and pEtN-cellulose fibrils [80,99,101] suggests
putative synergy specifically with antibiotics that are tolerated by biofilms due to their binding by
these matrix components.
6. Why do Plants Produce Antibiofilm Agents such as EGCG?
There is a huge body of literature on the therapeutic use of EGCG for various human diseases,
including neurodegenerative diseases, cancer and infectious diseases [59,128–130]. However,
EGCG-producing plants have neither evolved nor been bred to help humans treat diseases. So,
why do plants produce catechins and epicatechins in sometimes strikingly high concentrations, as is
the case for EGCG in Camellia sinensis [131]? Polyphenols in general are anti-oxidants and can protect
the producing plants, for example, against UV irradiation [132]). They have also been implicated in
resistance against bacterial or fungal plant pathogens [133–135], which is consistent with effects on the
expression of certain virulence genes as mentioned above.
As shown by recent studies [80,99,101], EGCG exhibits strong anti-amyloidogenic function at
much lower concentrations than antimicrobial effects (with E. coli, for instance, the formation of
amyloid curli fibres is inhibited at <50 µg/mL, whereas the minimal inhibitory concentration or MIC
is >10-fold higher)—a property indicating that EGCG is a potent anti-biofilm agent against bacterial
biofilms that contain amyloid fibres as a major extracellular matrix component. The same applies to
pEtN-cellulose fibrils, the production of which is equally inhibited by EGCG [80] and which are also
common in bacterial biofilm matrices [30]. The general question why plants produce EGCG can thus
be rephrased more specifically: do plants come into contact with bacterial biofilms containing amyloid
fibres or pEtN-cellulose to the point that they have to antagonize their deposition or formation on
their surfaces?
The life cycle of enteric bacteria such as E. coli or Salmonella, which occur in mammals, birds and
other animals, includes shedding into the environment [136]. Due to their general and specific stress
responses, these bacteria are well equipped to survive or even grow in very different and stressful
environments outside their hosts [137]. This includes bacterial life on the leaves of plants, i.e., in
the phyllosphere, where bacteria are exposed to nutrient limitation, desiccation and large changes in
temperature and UV irradiation [138,139]. Notably, from the bacterial perspective, firmly attaching
to plant leaves seems an attractive strategy to find a way back into the intestines of plant-eating
mammalian hosts. In fact, a number of reports have shown that curli fibres and pEtN-cellulose are
induced and involved in the formation of enteric biofilms on plant surfaces, both in the phyllosphere
and the rhizosphere [140–145].
On the other hand, plants—as with all macroorganisms—have to generally control bacterial
growth on their surfaces and, in particular, have to defend themselves against being colonized by
phytopathogenic bacteria. To achieve this, plants have evolved both constitutive and inducible defense
mechanisms based on the use of chemicals. While constitutive defense strategies include the production
of essential oils and various other secondary metabolites, inducible defense uses specific recognition
events that trigger molecular responses that lead to the production of reactive oxygen species, toxic
phytoalexins and signaling compounds such as salicylic acid, jasmonic acid and ethylene [146–149].
Antimicrobial action as well as specific effects of these compounds on virulence mechanisms have been
described in many studies [18,150]. However, instead of completely clearing bacteria and thereby
opening new niches for potentially worse pathogens, the plant phylosphere and rhizosphere are
associated with a complex microbiota [138,151]. Thus, plants actively promote the growth of beneficial
bacteria [152] and interfere with the growth of specific pathogens; e.g., by targeting the latter’s specific
virulence mechanisms [18].
Chemical communication implies that plants have to maintain their microbiota in an accessible and
manageable state; i.e., plants should ‘domesticate’ their microflora by inhibiting or at least controlling
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bacterial biofilm formation. Hence, plants can be expected to have evolved an arsenal of effective
anti-biofilm compounds. Seen from the plant perspective, producing high levels of EGCG most likely is
a strategy to interfere with the formation of amyloid and/or pEtN-cellulose-containing bacterial biofilms
on their surfaces. Directly targeting these extracellular matrix components also seems an attractive
strategy because, with this mode of action, anti-biofilm agents do not have to penetrate bacterial
cell envelopes, in contrast to compounds that would directly affect intracellular anti-biofilm targets
such as c-di-GMP-synthesizing diguanylate cyclases. Similarly, signaling pathways that respond to
cell envelope stress can be triggered from outside, which allows indirect manipulation of bacterial
gene expression or intracellular signaling. Notably, EGCG—like many polyphenols, a water-soluble
compound—acts from outside both on biofilm matrix fibre assembly and on a cell envelope stress
response that down-regulates the biosynthesis of the matrix fibre building blocks (summarized in
Figure 2). Finally, based on these general considerations as well as the specific findings for EGCG, we
may expect additional plant secondary compounds to show anti-biofilm activity—a hypothesis that
could direct future experimental studies.
7. Conclusions and Perspectives
As a compound with anti-amyloidogenic properties and the ability to interfere with the production
of bacterial pEtN-cellulose fibrils, EGCG is a potent inhibitor of the formation of certain types of
biofilms, namely those that use amyloid fibres and pEtN-cellulose as major extracellular matrix
components. As described above, this has been studied in most detail with E. coli [80], but seems to
apply for instance also to bacteria in oral biofilms [153]. Accordingly, EGCG alone or added to materials
used in dentistry has yielded promising results with respect to reducing the growth and/or surface
adhesion of S. mutans and caries formation [60,78,154–158]. Furthermore, EGCG is effective against
the formation of amyloids or amyloid-like fibres in biofilms of P. aeruginosa and S. aureus [99,101].
The anti-biofilm activity of EGCG against these two bacterial species, which are commonly found in
chronic wound infections, may thus add to other wound-healing effects of EGCG [159–162]. Topical
applications against oral or wound biofilms would also be less affected by the limited stability and
bioavailability of EGCG due to oxidation and degradation by the intestinal microbiota [163–166].
However, EGCG neither seems a general anti-biofilm agent nor do its specific anti-biofilm
properties necessarily lead to a reduction in biofilm-associated antibiotic tolerance. Under certain
conditions, EGCG was found to even promote biofilm formation and/or to increase tolerance of certain
antibiotics [126,127]. Certain cell envelope stress signaling pathways triggered by EGCG could lead
to a stress-protective response that actually promotes biofilm formation and the associated antibiotic
tolerance. Given the complexities of bacterial physiological reactions, beneficial effects of EGCG against
biofilms thus seem quite specific and conditional, with counterproductive effects not being excluded.
Amyloid curli fibres of enteric bacteria are not only important biofilm matrix components but
can also elicit pro-inflammatory effects in human hosts [51]. The temperature regulation of curli
is relaxed in many commensal or pathogenic intestinal E. coli; i.e., these strains express curli also
at human body temperature [47,48]. Antibodies against CsgA, the major curli subunit, have been
detected in serum from sepsis patients but not in healthy controls, and curli was shown to induce
a variety of proinflammatory cytokines [167], with curli being recognized by Toll-like receptors 1
and 2 [49,168,169]. Curli–DNA composites which can form in biofilm matrices can also stimulate the
auto-immune response underlying systemic lupus erythematosus [50]. Taken together, this suggests a
detrimental role of amyloid fibres produced by members of the human gut microbiota, which may be
relevant in the chronically inflamed intestine. Inflammatory bowel diseases are characterized by enteric
blooms; i.e., a strong increase in the relative abundance of mostly E. coli. These bacteria benefit from
and promote inflammation, thereby stabilizing the inflamed state [170]. That green tea polyphenols
are beneficial in the treatment of inflammatory bowel disease has been attributed to their effects on
various components of the host pro-inflammatory control network [170–173]. However, also processes
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on the bacterial side, i.e., a putative involvement of pro-inflammatory curli fibres in chronic intestinal
inflammation as well as the inhibition of curli production by EGCG, certainly deserve further study.
In general, a mutual interplay between EGCG and the gut microbiota seems to be currently
emerging as a new intriguing field of study [167]. EGCG has a beneficial effect in cancer therapy [165,174],
and specific microbiota-produced metabolites derived from EGC and EGCG were shown to interfere
with the proliferation of cervical cancer (HeLa) cells [175]. Both EGCG and its microbiota-generated
derivatives can scavenge toxic cellular reactive metabolites involved in the development of various
chronic diseases [176]. EGCG was also found to prevent or even counteract high-fat diet-induced
changes in the gut microbiota [177–179]. The specific processes underlying these beneficial effects
of EGCG are not fully understood, but it is already apparent that they are multifactorial. Direct
anti-oxidative effects by scavenging toxic reactive metabolites and the prevention of inflammation—both
by targeting specific components of the innate immune system and by inhibiting the production of
pro-inflammatory bacterial amyloids—are likely to operate synergistically in the molecular mechanism
of action of EGCG.
Humans have used plant-derived materials for medical purposes for a long time without knowing
or even asking how and why these agents were effective. Molecular biology is now unraveling the
molecular mechanisms of action. In addition, the ecophysiological relationships between plants,
bacteria, animals and humans now reveal why plants have evolved anti-amyloidogenic compounds
such as EGCG. These compounds do not only prevent the formation of biofilms on plant surfaces,
but at the same time can combat biofilms in chronic infections and even seem of value against toxic
amyloid-associated neuropathological diseases.
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